寻求疫苗诱导的预防结核病的免疫相关物。

Vaccine insights Pub Date : 2022-07-01 Epub Date: 2022-07-29 DOI:10.18609/vac/2022.027
Elisa Nemes, Andrew Fiore-Gartland, Cesar Boggiano, Margherita Coccia, Patricia D'Souza, Peter Gilbert, Ann Ginsberg, Ollivier Hyrien, Dominick Laddy, Karen Makar, M Juliana McElrath, Lakshmi Ramachandra, Alexander C Schmidt, Solmaz Shororbani, Justine Sunshine, Georgia Tomaras, Wen-Han Yu, Thomas J Scriba, Nicole Frahm
{"title":"寻求疫苗诱导的预防结核病的免疫相关物。","authors":"Elisa Nemes, Andrew Fiore-Gartland, Cesar Boggiano, Margherita Coccia, Patricia D'Souza, Peter Gilbert, Ann Ginsberg, Ollivier Hyrien, Dominick Laddy, Karen Makar, M Juliana McElrath, Lakshmi Ramachandra, Alexander C Schmidt, Solmaz Shororbani, Justine Sunshine, Georgia Tomaras, Wen-Han Yu, Thomas J Scriba, Nicole Frahm","doi":"10.18609/vac/2022.027","DOIUrl":null,"url":null,"abstract":"<p><p>Immunization strategies against tuberculosis (TB) that confer better protection than neonatal vaccination with the 101-year-old Bacille Calmette-Guerin (BCG) are urgently needed to control the epidemic, but clinical development is hampered by a lack of established immune correlates of protection (CoPs). Two phase 2b clinical trials offer the first opportunity to discover human CoPs against TB. Adolescent BCG re-vaccination showed partial protection against <i>Mycobacterium tuberculosis</i> (<i>Mtb)</i> infection, as measured by sustained IFNγ release assay (IGRA) conversion. Adult M72/AS01<sub>E</sub> vaccination showed partial protection against pulmonary TB. We describe two collaborative research programs to discover CoPs against TB and ensure rigorous, streamlined use of available samples, involving international immunology experts in TB and state-of-the-art technologies, sponsors and funders. Hypotheses covering immune responses thought to be important in protection against TB have been defined and prioritized. A statistical framework to integrate the data analysis strategy was developed. Exploratory analyses will be performed to generate novel hypotheses.</p>","PeriodicalId":75292,"journal":{"name":"Vaccine insights","volume":"1 3","pages":"165-181"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117634/pdf/","citationCount":"0","resultStr":"{\"title\":\"The quest for vaccine-induced immune correlates of protection against tuberculosis.\",\"authors\":\"Elisa Nemes, Andrew Fiore-Gartland, Cesar Boggiano, Margherita Coccia, Patricia D'Souza, Peter Gilbert, Ann Ginsberg, Ollivier Hyrien, Dominick Laddy, Karen Makar, M Juliana McElrath, Lakshmi Ramachandra, Alexander C Schmidt, Solmaz Shororbani, Justine Sunshine, Georgia Tomaras, Wen-Han Yu, Thomas J Scriba, Nicole Frahm\",\"doi\":\"10.18609/vac/2022.027\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Immunization strategies against tuberculosis (TB) that confer better protection than neonatal vaccination with the 101-year-old Bacille Calmette-Guerin (BCG) are urgently needed to control the epidemic, but clinical development is hampered by a lack of established immune correlates of protection (CoPs). Two phase 2b clinical trials offer the first opportunity to discover human CoPs against TB. Adolescent BCG re-vaccination showed partial protection against <i>Mycobacterium tuberculosis</i> (<i>Mtb)</i> infection, as measured by sustained IFNγ release assay (IGRA) conversion. Adult M72/AS01<sub>E</sub> vaccination showed partial protection against pulmonary TB. We describe two collaborative research programs to discover CoPs against TB and ensure rigorous, streamlined use of available samples, involving international immunology experts in TB and state-of-the-art technologies, sponsors and funders. Hypotheses covering immune responses thought to be important in protection against TB have been defined and prioritized. A statistical framework to integrate the data analysis strategy was developed. Exploratory analyses will be performed to generate novel hypotheses.</p>\",\"PeriodicalId\":75292,\"journal\":{\"name\":\"Vaccine insights\",\"volume\":\"1 3\",\"pages\":\"165-181\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117634/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccine insights\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18609/vac/2022.027\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/7/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine insights","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18609/vac/2022.027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/29 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

为了控制结核病流行,迫切需要针对结核病(TB)的免疫策略,这种免疫策略比新生儿接种101年历史的卡介苗(Bacille Calmette-Guerin, BCG)提供更好的保护,但缺乏确定的免疫相关保护(cop)阻碍了临床发展。两项2b期临床试验首次为发现抗结核病的人类cop提供了机会。通过持续IFNγ释放试验(IGRA)转换测量,青少年卡介苗再次接种显示出对结核分枝杆菌(Mtb)感染的部分保护。成人接种M72/AS01E疫苗对肺结核有部分保护作用。我们介绍了两个合作研究项目,旨在发现抗结核病的cop,并确保严格、简化地使用现有样本,涉及结核病领域的国际免疫学专家和最先进的技术、赞助商和资助者。已经确定并优先考虑了被认为对预防结核病很重要的免疫反应的假设。开发了一个集成数据分析策略的统计框架。探索性分析将被执行以产生新的假设。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

The quest for vaccine-induced immune correlates of protection against tuberculosis.

The quest for vaccine-induced immune correlates of protection against tuberculosis.

The quest for vaccine-induced immune correlates of protection against tuberculosis.

The quest for vaccine-induced immune correlates of protection against tuberculosis.

Immunization strategies against tuberculosis (TB) that confer better protection than neonatal vaccination with the 101-year-old Bacille Calmette-Guerin (BCG) are urgently needed to control the epidemic, but clinical development is hampered by a lack of established immune correlates of protection (CoPs). Two phase 2b clinical trials offer the first opportunity to discover human CoPs against TB. Adolescent BCG re-vaccination showed partial protection against Mycobacterium tuberculosis (Mtb) infection, as measured by sustained IFNγ release assay (IGRA) conversion. Adult M72/AS01E vaccination showed partial protection against pulmonary TB. We describe two collaborative research programs to discover CoPs against TB and ensure rigorous, streamlined use of available samples, involving international immunology experts in TB and state-of-the-art technologies, sponsors and funders. Hypotheses covering immune responses thought to be important in protection against TB have been defined and prioritized. A statistical framework to integrate the data analysis strategy was developed. Exploratory analyses will be performed to generate novel hypotheses.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信